Abstract 2066P
Background
This study aimed to assess the usefulness of ChatGPT and Perplexity's responses to frequently asked questions regarding the diagnosis and treatment of rectal cancer.
Methods
Both artificial intelligence systems were asked 20 questions covering disease risk factors, screening, symptoms, treatment, and treatment side effects. In accordance with the ESMO patient guides, the questions were posed in the order specified. According to ESMO patient guide recommendations, responses were graded as “appropriate,” “inappropriate,” or “insufficient.”
Results
While ChatGPT provided appropriate responses to 17 of the questions (85%), the responses to two questions (10%) were deemed inappropriate, and the response to one question (5%) was deemed insufficient. Nineteen (95%) of Perplexity's responses were deemed appropriate. It was determined that both artificial intelligence systems responded improperly to the nutrition question.
Conclusions
The study's findings indicate that ChatGPT and Perplexity provide patients with accurate information about rectal cancer. The accuracy rate of Perplexity was found to be higher than that of ChatGPT. It can be demonstrated that the benefit of Perplexity is that it displays the source for each piece of information. However, especially cancer patients require emotional and psychological assistance, and further research is required to determine the impact of these artificial intelligence systems on the patient's psychology. Moreover, given the complexity and individuality of medical care, AI chatbots should not be viewed as a replacement for medical professionals, but rather as a supplement that can help patients gain access to trustworthy information and support. Overall, this study contributes to the growing body of literature on AI chatbots and their potential use in cancer by highlighting both the advantages and disadvantages of these technologies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06